Fapon Biotech Introduces POCT Solution for COVID-19 E484K Mutation Testing -- MEDICA - World Forum for Medicine

19/02/2021

Fapon Biotech Inc.

Fapon Biotech Introduces POCT Solution for COVID-19 E484K Mutation Testing

Fapon Biotech makes persist efforts to deal with the global pandemic new challenge, introduces COVID-19 Variant E484K POCT Solution for the effective differentiation of E484K and non-E484K infection. Previously, the company took a significant innovative step for being the first in the world in launching POCT Solution for variant B.1.1.7 (VUI 202012/01) and wild-type virus differentiation (https://bit.ly/3qDsmky). These solutions using POCT mechanism to offer additional values to the variant diagnosis using genome sequencing and PCR technologies, being an excellent mean to fight against the global-spread of mutant viruses.

New challenges in E484K and other mutant strains identification

The 'escape mutation' E484K that firstly found in 501Y.V2 (B.1.351) and 501Y.V3 (B.1.1.28) variant strains in the South African and Brazilian has now spread to UK, Mayotte, Belgium, France, Switzerland and other countries according to GISAID.

E484K is named 'an escape mutation' because it helps the virus bypass the body's immune defences and weakens the protective effect of some vaccines. In February, South Africa halt its rollout of the Oxford-AstraZeneca vaccine after a study showed "disappointing" results against the new variant. A study from Cambridge University has even confirmed the combination of more transmissible variant B.1.1.7 and E484K mutation substantially increases the amount of serum antibody needed to prevent infection of cells.

Moreover, the Manaus city in Brazil that thought to reach herd immunity in the first wave are now experiencing a second outbreak, and the situation is fuelling by the COVID-19 variants. However, only 0.03% of cases in Brazil underwent genomic sequencing for variant identification due to the lacking of resources.

The fight of COVID-19 is facing new challenges caused by complex variants and mutation. As a mainstream COVID-19 raw material supplier to the global top-profile reagent manufacturers, Fapon Biotech continues to keep a close watch on the ever-changing pandemic situation and introduce products for other mainstream strain identification.

Exhibitor Data Sheet